<DOC>
	<DOCNO>NCT00429104</DOCNO>
	<brief_summary>Primary Objectives : 1 . To determine patient 's tumor response rate protocol produce . 2 . To determine 1 year progression-free survival protocol produce . Secondary Objective : 1 . To determine whether antibody-dependent cell-mediated cytotoxicity ( ADCC ) mechanism overcome Herceptin-resistance use Granulocyte-Macrophage Colony Stimulating Factor ( GM-CSF ) .</brief_summary>
	<brief_title>Herceptin GM-CSF Metastatic Breast Cancer</brief_title>
	<detailed_description>GM-CSF stimulate immune system may increase effectiveness Herceptin . Before start treatment study , call `` screening test . '' These test help doctor decide eligible take part study . You complete medical history physical exam . This include blood test ( 2 tea spoon ) , x-rays . Women able child must negative blood urine pregnancy test . If find eligible take part study , receive trastuzumab vein ( IV ) every week disease get bad . GM-CSF injected skin least day white blood cell count stable . GM-CSF also continue course study disease progress . You evaluation disease compute tomography-CT scan , bone scan , chest X-ray , etc . 2 , 4 , 6 , 9 , 12 , 18 , 24 month start treatment . You blood test ( 2 tea spoon ) least twice week appropriate dose GM-CSF found . The dose may increase decrease depend blood test . You blood ( 2 tablespoon ) draw treatment 2nd 4th month , disease get bad . You remove study disease progress severe side effect occur . This investigational study . The FDA approve trastuzumab GM-CSF , use study experimental . A total 36 patient take part study . All enrol UT MD Anderson Cancer Center .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Trastuzumab</mesh_term>
	<criteria>1 . Histological confirmation invasive carcinoma breast . 2 . HER2/neu overexpression : 3+ immunohistochemical stain Fluorescence situ hybridization ( FISH ) ( + ) . 3 . Stage IV breast cancer measurable disease . 4 . Patient receive progressive disease Herceptin plus chemotherapy Herceptin alone . No two Herceptin contain regimen . 5 . Zubrod performance status 0 1 . 6 . Adequate hematological parameter ( White Blood cellsWBC &gt; 3,000/mm3 , platelet count &gt; 100,000/mm3 ) , adequate renal function ( serum creatinine &lt; 2.0 mg/dl ) , adequate liver function ( total bilirubin , aspartate aminotransferase ( AST SGOT ) alanine aminotransferase ( ALT SGPT ) &lt; 3 x normal ) . 1 . Active Brain metastasis . 2 . No measurable disease time registration ( e.g . bone , leptomeningeal disease alone pleural effusion alone ) . 3 . More 2 Herceptin contain regimen metastatic breast cancer . 4 . Known history HIV positive . 5 . Chronic active hepatitis cirrhosis . 6 . Symptomatic pulmonary disease . 7 . Use steroid nonsteroidal antiinflammatory analgesic Cox2 inhibitor 1 week prior registration .</criteria>
	<gender>Female</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2012</verification_date>
	<keyword>Breast Cancer</keyword>
	<keyword>Carcinoma Breast</keyword>
	<keyword>HER-2/neu Overexpression</keyword>
	<keyword>Herceptin</keyword>
	<keyword>Trastuzumab</keyword>
	<keyword>GM-CSF</keyword>
	<keyword>Sargramostim</keyword>
	<keyword>Leukine</keyword>
</DOC>